Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study of Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines

NCT04889209 is registered in ClinicalTrials.gov with National Institute of Allergy and Infectious Diseases (NIAID) as lead sponsor.

NCT NCT04889209
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04889209 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study of Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Phase
Phase 1/2
Overall status
Completed
Start date
May 28, 2021
Completion date
June 16, 2023
Enrollment
867 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19